文献速递胸部肿瘤

晚期肺癌患者血浆游离DNA的超深度二代测序:可操作基因组联盟的研究结果

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
PubMed 文献 · Ann Oncol · 2019-01-01

前瞻性采集晚期进展期非小细胞肺癌患者血浆,用超深度二代测序检测37个肺癌相关基因,并与组织基因分型比较。血浆检测已知驱动基因的敏感性为75%(68/91),特异性为100%(19/19),并可在组织不足时发现KRAS突变及耐药机制。

要点

  • 血浆超深度二代测序检测已知驱动基因敏感性75%(68/91),特异性100%(19/19)。
  • 17例组织不足患者中,血浆检测发现4例KRAS突变。
  • 23例EGFR突变耐药患者中,血浆检测到T790M、C797S及ERBB2扩增等耐药机制。

核心结论

  • 超深度血浆二代测序结合克隆性造血过滤可从头检测可靶向驱动基因和耐药机制,包括组织活检不足以进行基因分型时。

研究设计与样本

  • 前瞻性采集晚期进展期非小细胞肺癌患者血浆,对血浆游离DNA和配对白细胞进行超深度二代测序,使用覆盖37个肺癌相关基因的杂交捕获panel,原始目标覆盖度50000×,过滤克隆性造血来源的体细胞突变。
  • 计算血浆检测已知驱动基因的临床敏感性和特异性,并与组织基因分型结果比较;在部分病例中进行正交ddPCR验证。

主要发现

  • 127例可评估患者中,血浆二代测序检测到驱动突变,变异等位基因频率范围为0.14%至52%。
  • 22例中21例血浆ddPCR检测EGFR或KRAS突变结果与血浆二代测序几乎一致,变异等位基因频率高度一致(r=0.98)。
  • 盲于组织基因型,血浆二代测序从头检测已知驱动基因的敏感性为75%(68/91)。
  • 组织二代测序驱动基因阴性者中,血浆二代测序特异性为100%(19/19)。
  • 17例肿瘤组织被判定不足以进行基因分型的患者中,血浆二代测序发现4例KRAS突变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought to develop an ultra-deep plasma next-generation sequencing (NGS) assay for patients with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations in patients where tissue biopsy failed to identify an actionable alteration. PATIENTS AND METHODS: Plasma was prospectively collected from patients with advanced, progressive NSCLC. We carried out ultra-deep NGS using cfDNA extracted from plasma and matched white blood cells using a hybrid capture panel covering 37 lung cancer-related genes sequenced to 50 000× raw target coverage filtering somatic mutations attributable to clonal hematopoiesis. Clinical sensitivity and specificity for plasma detection of known oncogenic drivers were calculated and compared with tissue genotyping results. Orthogonal ddPCR validation was carried out in a subset of cases. RESULTS: In 127 assessable patients, plasma NGS detected driver mutations with variant allele fractions ranging from 0.14% to 52%. Plasma ddPCR for EGFR or KRAS mutations revealed findings nearly identical to those of plasma NGS in 21 of 22 patients, with high concordance of variant allele fraction (r = 0.98). Blinded to tissue genotype, plasma NGS sensitivity for de novo plasma detection of known oncogenic drivers was 75% (68/91). Specificity of plasma NGS in those who were driver-negative by tissue NGS was 100% (19/19). In 17 patients with tumor tissue deemed insufficient for genotyping, plasma NGS identified four KRAS mutations. In 23 EGFR mutant cases with acquired resistance to targeted therapy, plasma NGS detected potential resistance mechanisms, including EGFR T790M and C797S mutations and ERBB2 amplification. CONCLUSIONS: Ultra-deep plasma NGS with clonal hematopoiesis filtering resulted in de novo detection of targetable oncogenic drivers and resistance mechanisms in patients with NSCLC, including when tissue biopsy was inadequate for genotyping.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Li BT, Janku F, Jung B, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol. 2019. PMID: 30891595. doi:10.1093/annonc/mdz046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。